Phase 2Recruiting
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Efficacy and Safety of TollB-001 Tablets in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Sponsor
- Toll Biotech Co. Ltd. (Beijing) (Industry)
- Enrolment
- 24 planned
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- TollB-001; Placebo
- Ages
- adults, older adults
- Registry
- NCT07408024
Full record on ClinicalTrials.gov
From the registry
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) .
Primary outcomes
- Safety-AE/lab tests/PE/VS/ECG
History
Primary completion expected
Last registry update
Registered
Started